Eposide

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Eposide

Property Description
Active ingredient Etoposide (VP-16)
Form Injection solution, Capsules
Pharmacological class Antineoplastic Agent, Cytotoxic Drug
Common use To inhibit malignant cell proliferation
Origin Semisynthetic (Podophyllotoxin derivative)

What Type of Medicine is Eposide?

Eposide is classified as a potent cytotoxic chemotherapy drug and a prescription-only medication belonging to the pharmacological class of antineoplastic agents. Its active pharmaceutical ingredient is Etoposide (VP-16), a crucial component in cancer therapy, which places it within a specialized group of medicines used to manage cell proliferation. As an antineoplastic agent, Eposide is fundamentally designed to exert an inhibitory effect on tumor growth, contributing a specific mechanism to the overall strategy of cancer management. Etoposide is used to stop the growth of cancer cells and is clinically recognized for its essential role in various treatment protocols.


Etoposide’s Composition, Origin, and Purpose

The core component, Etoposide, is a semisynthetic compound chemically derived from the plant compound podophyllotoxin. This specific origin, derived from a natural source but modified chemically, gives Etoposide its unique characteristics. Etoposide functions specifically as a DNA topoisomerase II inhibitor, targeting an enzyme crucial for the replication of genetic material within the cell. The general therapeutic purpose of Eposide is to induce breaks in the DNA strands of rapidly dividing cells, which ultimately triggers a programmed cell death process known as apoptosis. The drug has demonstrated activity across a range of rapidly proliferating tumors, confirming its versatility in the oncology setting.


Available Preparations of Eposide

Eposide is typically provided in multiple high-level pharmaceutical preparations, primarily as an injection solution and as oral capsules. The injection solution is intended for intravenous (parenteral) delivery, often utilizing a specific non-aqueous vehicle, and may be administered in a hospital setting. Conversely, the capsules provide a form for oral administration, containing Etoposide dissolved within an excipient system formulated for absorption. This dual availability—parenteral for rapid, supervised administration, and oral for convenient, sustained use—offers flexibility for healthcare providers in selecting the optimal delivery method based on a patient's specific clinical needs.

Regulatory References

  1. NIH/NCI Etoposide Term
  2. MedlinePlus

What side effects are possible with Eposide?

Eposide (Etoposide) safety information is officially classified by the frequency and organ system of adverse reactions, based on regulatory documentation. The safety profile is heavily weighted toward effects on the blood and immune systems, which are considered the primary dose-limiting toxicities.


Frequency-Classified Adverse Reactions

The most commonly documented adverse reactions include those in the Very Common category (ge 10%), such as myelosuppression (leukopenia, neutropenia, anemia, thrombocytopenia), which impacts the Blood and Lymphatic System. Gastrointestinal effects, including nausea, vomiting, mucositis, and anorexia, are also classified as Very Common. Alopecia (hair loss) is another highly frequent side effect documented in official labels.

Reactions categorized as Common (1% to <10%) include diarrhea, various types of hypersensitivity reactions, and transient hepatotoxicity. Uncommon reactions may involve peripheral neuropathy or transient hypertension. Rare documented events include serious conditions such as interstitial pneumonitis or toxic epidermal necrolysis.


Serious Safety Considerations

The most significant safety concerns explicitly documented in regulatory texts include potentially fatal myelosuppression and severe anaphylactic-like reactions. Official information also notes the association between Etoposide-containing regimens and the development of secondary leukemias (Acute Myeloid Leukemia). Administration safety notes specify that hypotension is linked to rapid intravenous infusion.

Safety constraints also apply to special populations, with specific regulatory notes regarding reduced drug clearance in patients with renal impairment and the potential for fetal harm during pregnancy.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information for Eposide (Etoposide) overdose strictly defines manifestations and required emergency actions, emphasizing that immediate medical attention is necessary upon any suspected overexposure. The documented clinical profile of an overdose centers on profound and severe myelosuppression, which is the primary dose-limiting toxicity. This includes severe leukopenia, thrombocytopenia, and granulocytopenia, leading to potentially fatal outcomes such as uncontrolled infection and hemorrhage.


Required Emergency Response

The regulatory labeling mandates that patients or caregivers seek immediate medical attention and contact emergency services or a poison control center right away. Urgent medical assessment is required due to the severity and potential delayed onset of toxicity. No specific antidote is known for Etoposide overdose. Therefore, treatment, as defined by official documents, must be strictly symptomatic and supportive, including blood product transfusions (e.g., platelet support) and the management of associated infections.

Close, continuous monitoring of hematologic status via serial blood counts and extended hospital observation may be necessary. A population-specific note highlights an increased susceptibility to severe toxicity in patients with pre-existing renal impairment.

Therapeutic Uses of Eposide

What Eposide Treats: Main Uses and Benefits

Eposide (Etoposide) is generally considered relevant for managing conditions marked by increased discomfort or tension associated with malignant diseases. Its primary use may be part of symptomatic management within intensive, multi-agent chemotherapy regimens for severe, high-risk cancers.


This therapy is commonly used across conditions presenting with a high symptomatic burden, and is used for managing key indications such as Small Cell Lung Cancer (SCLC), advanced or refractory Testicular Cancer, Acute Myeloid Leukemia (AML), specific lymphomas, and the life-threatening condition Hemophagocytic Lymphohistiocytosis (HLH). Eposide is commonly used in situations involving certain distressing symptoms associated with high-burden malignant conditions.

Its application is particularly relevant when symptoms intensify, such as in cases of relapsed or refractory disease, and may assist with easing symptoms related to physical discomfort caused by tumor mass. This supportive approach helps patients cope more steadily with the difficult episodes associated with these high-burden diseases.

“Eposide is applied in scenarios where additional symptomatic support is needed, and is relevant when supportive symptom management is appropriate in high-burden, progressing disease.”


Quick Fact: Symptomatic Support
Supports maintaining functional stability and contributes to easing the overall symptom load for patients facing advanced or recurrent disease presentations.

Eligibility and Restrictions for Use

Who Can and Cannot Use Eposide?

The official eligibility for Eposide (Etoposide) is strictly defined by regulatory documents, focusing on patient status, organ function, and reproductive health.

Eposide is contraindicated and must not be used by patients with a known hypersensitivity to etoposide or any of its formulation components. Use is also prohibited in individuals with pre-existing severe myelosuppression unless the low blood counts are caused by the malignant disease itself. Concomitant use with Yellow fever vaccine or other live vaccines is a formal contraindication.

Population Group Eligibility Status (Regulatory Wording)
Pregnancy/Lactation Contraindicated (Pregnancy Category D); Lactation must be discontinued.
Renal Impairment Restricted use: A reduced initial dose is required for patients with creatinine clearance between 15 and 50 mL/min.
Severe Hepatic Impairment Contraindicated in some official labels.
Pediatric Population Safety and efficacy have not been established for all approved adult indications.

For patients of childbearing potential, effective contraception is required during and for a period after treatment. Geriatric patients are generally eligible, but caution is advised due to the potential for decreased organ function.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes documented interaction patterns between Eposide (Etoposide) and other substances, as officially stated by regulatory authorities.


Official Interaction Statements

  • Co-administration with live vaccines is contraindicated due to the immunosuppressive effects of Etoposide, which may increase the risk of serious infection.
  • The use of P-glycoprotein (P-gp) inhibitors (e.g., Cyclosporine) may cause a significant increase in the systemic exposure (AUC) of Etoposide.
  • Co-administration with CYP3A4 inducers (e.g., Phenytoin, Carbamazepine, Rifampicin) may reduce the plasma concentration of Etoposide by increasing its metabolic clearance.
  • The use of Warfarin concurrently with Etoposide may result in an elevated International Normalized Ratio (INR), indicating an enhanced anticoagulant effect.
  • Consumption of Grapefruit Juice or the use of St. John's Wort may alter the bioavailability or reduce the exposure of Eposide and is generally advised to be avoided.
  • Impaired renal function is officially documented to reduce Eposide clearance and increase its AUC, requiring consideration due to this patient-specific factor.

Interaction Classification Summary

Classification Interacting Product Category Official Outcome
Contraindicated Live Vaccines Increased risk of serious infection.
Exposure Modification P-gp/CYP3A4 Modulators Increase or decrease in Etoposide plasma concentration.
Pharmacodynamic Warfarin Elevated INR (anticoagulant effect enhancement).

The official profile mandates caution for products that modulate P-gp or CYP3A4, as these alter Eposide exposure. The primary restriction is the contraindication with live vaccines.

Mechanism of Action

Eposide (Etoposide/VP-16) operates via a specific mechanism that acts on DNA topoisomerase II and disrupts the machinery essential for cell division. The mechanism involves two core, sequential domains: molecular poisoning and programmed cellular elimination.


Molecular Poisoning of DNA Topoisomerase II

This domain covers Eposide's direct interaction with its molecular target, the nuclear enzyme DNA topoisomerase II (Topo II). Eposide acts as a Topo II poison by stabilizing the enzyme after it has cut the DNA strands, thereby preventing the necessary religation step. This key action results in the accumulation of persistent double-strand DNA breaks (DSBs) within the nucleus.


Forced Cell Cycle Arrest and Apoptosis

The persistent DSBs trigger the cell's internal safety system, enforcing a crucial halt at the G2/ M cell cycle checkpoint. This inability to repair the genome and proceed with division activates the intrinsic pathway of apoptosis (programmed cell death). This cascade leads to the physiological inhibition of proliferation, a process characteristic of high-turnover cell populations, which represents the final physiological consequence of the drug's mechanism.

Dosage and Administration Information

Eposide (Etoposide) is administered according to standardized, high-level protocols. The medicine is available for use as a slow intravenous (IV) infusion from a concentrate solution or via oral capsules.

Official Administration Protocols

Dosing Calculation and Schedule The amount of Eposide is precisely calculated based on the patient's Body Surface Area (BSA), measured in mg/m^2. Treatment follows a cyclic regimen, where the dose is administered daily for a short, consecutive period, typically 3 to 5 days. This course is followed by a mandatory rest interval, with cycles often repeating every 21 to 28 days. Oral dosing is generally calibrated to be approximately double the IV dose to achieve similar systemic exposure.

Preparation and Constraints The intravenous concentrate must be diluted to a concentration not exceeding 0.4 mg/mL before use. The diluted solution must then be delivered by slow infusion, a required procedural condition that mandates administration over a period of 30 to 60 minutes; rapid injection is prohibited.

Population-Specific Adjustments Dose modification is required for specific populations. A crucial example is patients with moderate renal impairment (creatinine clearance 15 to 50 mL/min), who receive a reduced dose of 75% of the standard regimen to ensure procedural compliance.

Recent Clinical Evidence

Research Evidence and Overview of Studies for Eposide


Evidence for use in Small Cell Lung Cancer (SCLC)

This section summarizes the main research that has examined Eposide in the context of Small Cell Lung Cancer (SCLC), which is a condition characterized by rapid cell division. The research has explored primarily clinical trials, where Eposide was studied for its use alongside other established therapies. The content will focus on how these studies evaluated tumor response and patient outcomes.

Research so far indicates that when Eposide is used as part of a combination regimen, studies examined outcomes related to physical discomfort and monitored patterns of disease evolution. The findings help contextualize how patients reported their experience during the study periods.

Evidence for use in Testicular Cancer

Clinical research has explored Eposide as a component of treatment plans for testicular cancer. Most of the evidence available was observed in controlled clinical settings where patients were evaluated in studies comparing different therapeutic approaches. The goal of this research was studied for its impact on managing tumor activity.

Long-term Studies and Follow-up

While many studies were conducted during the initial phases of treatment, information on the very long-term effects are not fully established. Current findings describe patterns observed in the studies over defined time intervals. However, follow-up durations were limited in many of the key trials. Therefore, data are still emerging regarding the overall patterns observed in the studies over extended periods and how the use of Eposide may relate to patient outcomes years after treatment is completed.

Evidence in Special Populations

Research examined how Eposide was evaluated in specific patient groups that may require different considerations than the general adult population. For instance, studies have explored its use in children, and those with pre-existing conditions affecting the kidneys or liver. For these groups, data for certain groups remain insufficient, and the available evidence is limited.

What is Still Uncertain About Eposide

While many studies have explored Eposide, several important questions remain open. One area where comparative evidence is lacking is how Eposide directly compares to newer or alternative treatments in head-to-head trials for its approved uses. Additionally, findings were mixed in some research areas, and scientists continue to study the reasons behind the variety of outcomes reflecting daily functioning or activity level observed in the studies.

Frequently Asked Questions (FAQ)

Common questions about Eposide (FAQ)


Q: Are there any common foods or supplements that should be avoided when using Eposide?

Official product information indicates that some substances may affect how the medicine works in the body. Specifically, the supplement St. John's Wort and Grapefruit Juice are described as potentially altering the drug's exposure, and official information notes that they are typically avoided.


Q: Can Eposide be used by people who have other existing health conditions?

The eligibility for Eposide is strictly defined by official documents based on existing conditions. The use is restricted for patients with conditions such as severe myelosuppression (low blood counts), severe hepatic (liver) impairment, and renal (kidney) impairment, for which official information indicates a reduced initial dose is required.


Q: Does Eposide contain any ingredients that might cause an allergic reaction?

Official documentation describes that use is contraindicated if there is a known hypersensitivity to the active ingredient, etoposide, or any other component of the formulation. For the injection, these non-active components (excipients) include dehydrated alcohol and polysorbate 80.


Q: Are there any long-term effects of Eposide use that have been studied?

Regulatory warnings note that Eposide-containing treatment regimens have been associated with the development of a specific type of blood cancer called secondary leukemia (Acute Myeloid Leukemia). This is a known risk that is documented in the official safety information.


Q: Can Eposide cause problems with sleep?

The official list of very common side effects does not include sleep problems or insomnia. However, the product documentation notes that less common central nervous system effects, such as dizziness or confusion, have been reported by users.


Q: Does Eposide have any known effects on mood or mental focus?

Official regulatory documents do not list specific effects on mood or mental focus. However, central nervous system effects are documented, with less common reactions that include feelings of confusion reported by some users.


Q: Is it normal to feel tired or dizzy after starting Eposide?

According to official adverse reaction lists, feelings of unusual tiredness or weakness are reported as common effects. Similarly, dizziness or faintness is also noted as a possible effect in the regulatory documentation.


Q: Is there a generic version of Eposide available?

Yes, the active ingredient in Eposide is Etoposide (VP-16), which is available in a generic formulation. The generic name is used throughout the official product documentation.


Q: Is Eposide known to cause weight changes?

Official product information lists changes in weight as a documented adverse reaction. Specifically, weight loss is reported as a common effect in the regulatory documents.


Q: Does alcohol interact with Eposide?

Regulatory warnings highlight that the injection solution contains ethanol (alcohol) as an inactive component. This specific component carries a warning for patients with pre-existing conditions like alcoholism or liver disease.


Q: What is the expected duration of the effects of Eposide after each use?

Official documents contain pharmacokinetic data that describes how long the medicine remains active in the body. The drug is eliminated in two phases, with the main half-life of the medicine measured at approximately 11.5 hours.


Q: Is Eposide addictive or habit-forming?

According to official regulatory classification, Eposide is a prescription-only medicine that does not have a DEA schedule. This means the medicine is not considered a controlled substance with potential for abuse or dependence.


Q: What kind of specialist usually prescribes Eposide?

Official documentation describes that the administration and supervision of this medicine occurs under a physician who is experienced in the use of chemotherapeutic agents.


Q: Are there known differences in how Eposide works for men versus women?

Analysis of safety data from post-marketing surveillance suggests that certain high-risk adverse events may show different patterns of occurrence or signals between male and female patients.


Q: What does official guidance say about missing a use of Eposide?

Official guidance regarding a missed use is available in the prescribing information. This guidance details the specific steps to follow based on how much time has passed since the scheduled administration.


Q: How quickly do the side effects of Eposide usually go away after stopping use?

The time it takes for side effects to resolve varies, but official documentation provides a clear timeline for the most critical effect. For myelosuppression (low blood counts), bone marrow recovery is usually complete within approximately 20 days after administration of the medicine.


Q: Why is Eposide used to treat multiple conditions?

The drug's therapeutic action is based on its mechanism of action: inhibiting the enzyme DNA Topoisomerase II. Because this action disrupts the cell division of various fast-proliferating cells, it provides the basis for the medicine's use across multiple different conditions.


Q: What is the definition of the main condition Eposide treats?

Eposide is used to treat conditions such as Small Cell Lung Cancer (SCLC) and certain types of testicular cancer. These are the conditions for which the medicine has been studied and approved for use.


Q: Can people who are physically active or athletes use Eposide?

Due to the common risk of myelosuppression (low blood cell counts), official safety guidance states that avoiding contact sports or situations where bruising or injury could occur is necessary.


Q: What information is available about Eposide and driving or operating machinery?

Official adverse event lists include effects such as dizziness and confusion. Because these side effects can affect a person's attention and coordination, the occurrence of dizziness and confusion is a factor to consider before performing activities like driving or operating machinery.

How should Eposide be stored and disposed of?

How to Store and Dispose of Eposide (Etoposide)

Eposide storage requirements differ based on the preparation and must adhere to official label instructions to maintain stability.

Preparation Required Storage Conditions
Injection (Vials) Store at controlled room temperature (20 C to 25 C). Keep in the original container, upright, and protect from light.
Capsules Store under refrigeration (2 C to 8 C). Keep in the original container and protect from excessive heat.

All Eposide formulations must be stored out of the sight and reach of children.

Disposal Instructions:

Unused or expired Eposide is classified as a cytotoxic drug and must not be discarded in household waste or via wastewater. Disposal must follow the local procedures for cytotoxic waste as directed by regulatory authorities.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Eposide found in:

A-Z Index: